Gene · 25913
NIH grants1,830
NIH grants whose papers are about the gene, through NIH's grant-paper links.
181 to 200 of 1,830
Download this page as JSON| Grant | Title | POT1 papers | Newest fiscal year |
|---|---|---|---|
| R01GM134681 | The role of DNA damage tolerance pathways in human cells | 1 | 2025 |
| R01GM146376 | Molecular Basis of Coats Plus Disease | 1 | 2025 |
| R01GM153806 | Mechanism of the Human Telomere C-Strand Fill-In Machinery Assembly and Activation at Chromosome Ends | 1 | 2025 |
| R01HG005853 | Mapping dynamic functional networks across environments and backgrounds | 1 | 2025 |
| R01HL092577 | IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVAL | 1 | 2025 |
| R01HL127349 | Genomic Analysis of Tissue and Cellular Heterogeneity in IPF | 1 | 2025 |
| R01HL128239 | Genetic and molecular basis for SRSF2 mutations in myelodysplasia | 1 | 2025 |
| R01HL130020 | Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCs | 1 | 2025 |
| R01HL132523 | Early Origins of Chronic Lung Disease: From Birth to Age 45 Years | 1 | 2025 |
| R01HL133040 | Lipidomics and structural genomics of cardiometabolic health in Samoan adults | 1 | 2025 |
| R01HL134776 | The Wnt7a/ROR2 axis in the pathogenesis of pulmonary arterial hypertension | 1 | 2025 |
| R01HL135142 | Genetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung Abnormalities | 1 | 2025 |
| R01HL139897 | Lung Remodeling Mediated by Telomere Dysfunction in Alveolar Type II Cells | 1 | 2025 |
| R01HL146690 | Human iPSC Model to Elucidate Metabolic Interplay in Diabetic Cardimyopathy | 1 | 2025 |
| R01HL148333 | The molecular pathophysiology of the congenital dyserythropoietic anemias | 1 | 2025 |
| R01HL158691 | Obesity-induced dysfunction of human MSC in peripheral microvascular repair | 1 | 2025 |
| R01NR019610 | Early Life Experience and Childhood Telomere Biology: A Longitudinal Study of Developmental Context and Behavioral Mediators | 1 | 2025 |
| R01NS017950 | Precursors of Stroke Incidence and Prognosis | 1 | 2025 |
| R01NS076991 | Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and Leukodystrophies | 1 | 2025 |
| R24AA025017 | Clinical Resource for Alcoholic Hepatitis Inestigation | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25913/grants?page=10